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Conclusion The low-dose salivary DST test in its current 
form is not suitable for use in clinical practice in children 
with asthma, due to low reproducibility. Therefore, stud-
ies using the 0.25 mg salivary DST should be interpreted 
cautiously.
Keywords Glucocorticoid sensitivity · Paediatric 
endocrinology · Asthma
Introduction
Inhaled corticosteroids (ICS) are the cornerstone of treat-
ment in children with persistent asthma [1]. However, there 
is considerable inter-individual variation regarding the 
response to ICS and side effects. Overtreatment with ICS 
may decrease height velocity, increase weight and induce 
(partial) adrenal insufficiency, whereas undertreatment 
may cause persisting asthmatic complaints, exacerbations, 
unscheduled health care visits and reduced quality of life. 
A simple and fast test to predict glucocorticoid sensitivity 
would enable more tailored therapy.
The 0.25 mg dexamethasone suppression test (DST) 
was developed to assess individual glucocorticoid sensi-
tivity [2]. As opposed to the 1 mg DST (used to diagnose 
Cushing’s syndrome), the 0.25 mg DST only partially sup-
presses cortisol levels. The Gaussian distribution of post-
dexamethasone cortisol levels in 164 healthy adults reflects 
inter-individual differences in glucocorticoid sensitivity 
[2]. Hypersensitive persons suppress their HPA-axis more 
in the 0.25 mg DST than resistant persons.
Our objectives were (1) to investigate the reproducibility 
of an overnight 0.25 mg DST, using salivary cortisol levels, 
in children with asthma and (2) to investigate the utility of 
this test as a marker for glucocorticoid sensitivity.
Abstract 
Purpose Inhaled corticosteroids (ICS) are the cornerstone 
of asthma treatment in children. However, there is consider-
able inter-individual variation in glucocorticoid sensitivity, 
leading to over- as well as undertreatment. A simple and 
fast test to predict glucocorticoid sensitivity would enable 
more tailored therapy in children with asthma.
Aim To study reproducibility and utility of an overnight 
0.25 mg dexamethasone suppression test (DST) with sali-
vary cortisol levels as marker for glucocorticoid sensitivity 
in asthmatic children.
Methods 23 children with atopic asthma were recruited 
for two overnight 0.25 mg DST’s, 1 month apart.
Results Baseline cortisol levels correlated well between 
both tests. However, cortisol levels, change in cortisol lev-
els or fractional suppression of cortisol levels after dexa-
methasone did not correlate between the two tests. Bland–
Altman plots showed that the difference in salivary cortisol 
levels between test 1 and 2 of an individual patient could 
go up to 12 nmol/l, which is a clinically relevant difference. 
ICS dose did not correlate with baseline cortisol levels, 
height and BMI SDS.
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Methods
This pilot study was embedded in the multi-centre study 
‘Better Asthma Treatment: Monitoring with Asthma Con-
trol Test (ACT) and Nitric oxide’ (BATMAN) [3]. The local 
Ethics Committee approved the study. All patients (when 
aged ≥12 years) and parents gave informed consent.
23 Children with atopic asthma sampled saliva in the 
morning, ingested dexamethasone in the evening and pro-
vided a second sample the morning thereafter. To evaluate 
reproducibility, the same test was repeated after 1 month in 
16 children, without changing the ICS dose.
Participants discontinued ICS and topical corticos-
teroids, during test days only. The dexamethasone dose 
(based on the 0.25 mg DST for adults) was adjusted to the 
children’s weight (3.33 µg/kg bodyweight, rounded off to 
50 µg units; maximum dose 0.25 mg).
Salivary cortisol levels were measured using a commer-
cial enzyme immunoassay (DRG Salivary Cortisol ELISA 
SLV-2930, DRG International, USA) with intra- and inter-
assay coefficients of variation <6 and <9 %, respectively.
To correlate the DST with ICS dose, a standardized ICS 
dose of budesonide equivalent in μg/day was calculated 
from the dose and type of ICS the participant was using 
(100 μg beclomethasone extra fine = 200 μg beclometh-
asone = 100 μg fluticasone = 200 μg budesonide) [4]. 
Fractional suppression of cortisol after dexamethasone was 
calculated as ((pre-dex cortisol − post-dex cortisol)/pre-
dex cortisol) × 100 (%).
A power calculation showed that, based on a 2-sided 
test, sample size 16, alpha 5 %, we had 80 % power to 
detect a 1 SD difference in post-dexamethasone salivary 
cortisol levels (~5 nmol/l) between test 1 and test 2.
Bland–Altman plots (the differences between two 
repeated measurements for each subject plotted against the 
mean of those measurements) were produced for pre- and 
post-dexamethasone cortisol levels. As a measure of repeat-
ability, the 95 % limit of agreement was calculated. This 
indicates how far apart measurements on two different time 
points may be for individual patients. If differences within 
this limit are not clinically important, the measurement is 
considered reproducible.
Results
23 Children (6 females), mean age 12.1 years (95 %CI 
10.9–13.4), were included (Table 1). Most children (17/23) 
had lower salivary cortisol levels after dexamethasone, 
although 6/23 children showed an increase. Basal morn-
ing cortisol levels in test 1 and 2 correlated significantly 
(r = 0.66; p = 0.017).
Cortisol levels after dexamethasone, change in cortisol 
levels and fractional suppression of cortisol after dexa-
methasone did not correlate between test 1 and 2 (r = 0.51; 
p = 0.1, r = 0.42; p = 0.1 and r = 0.28; p = 0.2, respec-
tively). Basal salivary cortisol levels were below the refer-
ence (8–30 nmol/l) in 9/23 (39 %) and 8/16 (50 %) children 
at test 1 and 2, respectively. However, only 3 children had 
reduced levels in both tests.
Bland–Altman plots show that the mean difference for 
both basal and post-dexamethasone levels was not signifi-
cantly different from zero, indicating no fixed bias between 
tests 1 and 2 (Fig. 1). The 95 % limits of agreement, indi-
cating how far apart measurements on the two occasions 
were likely to be for most individuals, were 12.9 nmol/l for 
basal cortisol levels and 12.5 nmol/l for post-dexametha-
sone measurements.
ICS dose, uncorrected or expressed as μg/kg, μg/BSA 
or μg/age, did not correlate with baseline cortisol levels nor 
differed between those subjects with basal salivary cortisol 
levels below vs. within/above the reference. ICS dose and 
baseline cortisol levels did not correlate with height SDS or 
BMI SDS.
Discussion
This pilot study is the first to investigate reproducibility 
and utility of the 0.25 mg DST using salivary cortisol as 
a marker for glucocorticoid sensitivity in children with 
asthma. We studied reproducibility by performing two low-
dose DST’s in the same children, 1 month apart, without 
changing their maintenance ICS.
The low-dose or 0.25 mg DST is an innovative and easy 
applicable method to assess glucocorticoid sensitivity. 
Various authors reported associations with glucocorticoid 
sensitivity determining genotypes [5–8]. The test has been 
Table 1  Clinical characteristics at baseline
All values expressed as mean (95 % CI), apart from gender
a A value of >19 is considered good asthma control
Total group Reproducibility group
N 23 16
Age (years) 12.1 (10.9–13.4) 12.6 (11.2, 14.1)
Gender (m/f) 17/6 12/4
Height SDS −0.5 (−1.1, 0.4) −0.5 (−1.2, 0.2)
BMI SDS 0.6 (0.1, 1.1) 0.7 (0.0, 1.3)
ICS dose per kg (mcg) 11.0 (9.1, 12.9) 11.5 (9.2, 13.8)
Asthma control test scorea 22 (21–24) 23 (21–24)
Compliance (ICS use in 
days per week)
6.5 (6.2–6.8) 6.4 (6.0–6.8)
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popular in psychology/psychiatry research, where some 
authors found correlations between the degree of cortisol 
suppression and clinical parameters [9, 10]. Both plasma 
[6, 8, 10] and salivary [5] cortisol measurements have been 
used in these studies. However, reproducibility of the low-
dose DST has not received much attention in the scientific 
literature.
We found a good correlation, but low reproducibility 
of baseline cortisol levels. Our data indicate considerable 
variation in repeated measures of salivary cortisol, up to 
12 nmol/l. As the analytical variation of the test is only 
9 %, this suggests considerable within-subject (biological) 
variation. Common upper respiratory tract infections and/or 
psychosocial stress might have contributed to this variation. 
In addition, post-dexamethasone salivary cortisol levels, 
absolute change and fractional suppression of salivary cor-
tisol levels after dexamethasone did not correlate between 
the two tests. This shows that the 0.25 mg DST had a poor 
reproducibility in our study.
Previous studies investigating the reliability of HPA-axis 
measures are scarce and most studies using low-dose DST’s 
have been performed in adults. Golden et al. reviewed reli-
ability of several assessment methods of the HPA-axis 
[11]. In keeping with our findings, an 8 am salivary cortisol 
had the lowest between-visit reliability (R = 0.18–0.47). 
Reliability of a 0.5 mg DST was considered reasonable 
(R = 0.42–0.66). Wingenfeld et al. [12] also studied repro-
ducibility of the 0.5 mg DST and found a significant cor-
relation between the fractional cortisol suppression for a 
4 pm sample, but only a borderline correlation for the 8 am 
sample. Because a higher dexamethasone dose will result 
in a greater or complete suppression of cortisol, the 0.5 mg 
DST is more likely to be reproducible. However, higher 
doses of dexamethasone will result in less variation in the 
degree of cortisol suppression and are therefore less suit-
able to determine glucocorticoid sensitivity. Reproducibil-
ity of the 0.25 mg DST, using either serum or saliva, was 
studied only once before, in adults, by Reynolds et al. [13]. 
In 29 healthy subjects, salivary cortisol levels (post-dexa-
methasone) had much more within-subject variation than 
plasma cortisol levels [13]. The authors suggested sampling 
problems (e.g. variable salivary flow rates) or a poor cor-
relation between salivary and plasma cortisol levels at low 
concentrations (post-dexamethasone) as an explanation. 
Our study is the first to investigate reproducibility of the 
low-dose DST in children.
Reduced basal salivary cortisol levels have been reported 
in children and adults with asthma on steroid treatment [14, 
15], suggesting that an effect of ICS on the HPA-axis can 
be measured with salivary cortisol samples. In our study, 
three children showed repeated basal cortisol levels below 
the reference. Lower basal cortisol levels in children with 
asthma could reflect partial adrenal insufficiency, which 
might warrant evaluation by paediatric endocrinology, if 
there are clinical symptoms.
In conclusion, our study shows that the low-dose sali-
vary DST test in its current form is not suitable for use in 
clinical practice in children with asthma, due to low repro-
ducibility. Therefore, studies using the 0.25 mg salivary 
DST should be interpreted cautiously.
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Fig. 1  a Bland–Altman plot for salivary cortisol levels before dexa-
methasone test 1 vs. test 2. The line ‘mean’ indicates the mean differ-
ence between test 1 and 2 for all participants. Also, the 95 % CI for 
the difference between test 1 and 2 is indicated, showing that there 
is considerable variation between test 1 and 2, and thus poor repro-
ducibility. b Bland–Altman plot for salivary cortisol levels after dexa-
methasone test 1 vs. test 2
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